Achieving shared treatment decisions

Martin H. N. Tattersall, David W. Kissane

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Reaching treatment decisions in oncology often involves trade-offs between quality of life and quality of quantity of life. Decisions are best informed by evidence and patients need to understand that their engagement in decision-making is desirable because frequently there is not one best treatment and their values, preferences, and goals are important in reaching shared treatment decisions.

In the screening context, screening may identify abnormality that is not cancer but still merit surgery. Some cancers detected by screening may have already metastasized, and the consequence of 'early detection' is extended survival with incurable disease, rather than normal life expectancy. In the adjuvant setting, not every person recommended treatment experiences disease recurrence even if they choose not to receive chemotherapy. Adjuvant treatment may be the standard of care, but patients need to understand that disease recurrence is possible, and the outcome may be extension of disease-free survival, and not disease elimination. In patients with metastatic cancer, systemic treatments at the best may cause tumour shrinkage and prolongation of survival, but some patients will derive no benefit and experience the side effects of chemotherapy.

The Institute of Medicine defined patient-centred care as 'care that is respectful of and responsive to individual patient preferences, needs and values' (Barry and Edgman-Levitan 2012, p.780). Involving patients in discussions about treatment options and reaching of shared treatment decision highlights the importance of doctors and patients working together to produce the best outcome possible. Shared decision-making is applicable to most clinical consultations. It is especially important in circumstances where the evidence does not strongly support a single clearly superior option or where a preference-sensitive decision is involved, that is, the decision is likely to be strongly influenced by patient's preferences and values (Hoffmann et al. 2014). Shared decision-making enables research evidence to be incorporated into discussions with the patient, with their preferences explored and considered in reaching a treatment recommendation.
Original languageEnglish
Title of host publicationOxford Textbook of Communication in Oncology and Pallative Care
EditorsDavid W. Kissane, Barry D. Bultz, Phyllis N. Butow, Carma L. Bylund, Simon Noble, Susie Wilkinson
Place of PublicationOxford UK
PublisherOxford University Press
Pages83-90
Number of pages8
Edition2nd
ISBN (Print)9780198736134
Publication statusPublished - 2017

Keywords

  • metastatic cancer; communications skills program; shared decison making

Cite this

Tattersall, M. H. N., & Kissane, D. W. (2017). Achieving shared treatment decisions. In D. W. Kissane, B. D. Bultz, P. N. Butow, C. L. Bylund, S. Noble, & S. Wilkinson (Eds.), Oxford Textbook of Communication in Oncology and Pallative Care (2nd ed., pp. 83-90). Oxford UK: Oxford University Press.
Tattersall, Martin H. N. ; Kissane, David W. / Achieving shared treatment decisions. Oxford Textbook of Communication in Oncology and Pallative Care. editor / David W. Kissane ; Barry D. Bultz ; Phyllis N. Butow ; Carma L. Bylund ; Simon Noble ; Susie Wilkinson. 2nd. ed. Oxford UK : Oxford University Press, 2017. pp. 83-90
@inbook{ff7b58d3eb9942e891db5ea8515390c8,
title = "Achieving shared treatment decisions",
abstract = "Reaching treatment decisions in oncology often involves trade-offs between quality of life and quality of quantity of life. Decisions are best informed by evidence and patients need to understand that their engagement in decision-making is desirable because frequently there is not one best treatment and their values, preferences, and goals are important in reaching shared treatment decisions.In the screening context, screening may identify abnormality that is not cancer but still merit surgery. Some cancers detected by screening may have already metastasized, and the consequence of 'early detection' is extended survival with incurable disease, rather than normal life expectancy. In the adjuvant setting, not every person recommended treatment experiences disease recurrence even if they choose not to receive chemotherapy. Adjuvant treatment may be the standard of care, but patients need to understand that disease recurrence is possible, and the outcome may be extension of disease-free survival, and not disease elimination. In patients with metastatic cancer, systemic treatments at the best may cause tumour shrinkage and prolongation of survival, but some patients will derive no benefit and experience the side effects of chemotherapy.The Institute of Medicine defined patient-centred care as 'care that is respectful of and responsive to individual patient preferences, needs and values' (Barry and Edgman-Levitan 2012, p.780). Involving patients in discussions about treatment options and reaching of shared treatment decision highlights the importance of doctors and patients working together to produce the best outcome possible. Shared decision-making is applicable to most clinical consultations. It is especially important in circumstances where the evidence does not strongly support a single clearly superior option or where a preference-sensitive decision is involved, that is, the decision is likely to be strongly influenced by patient's preferences and values (Hoffmann et al. 2014). Shared decision-making enables research evidence to be incorporated into discussions with the patient, with their preferences explored and considered in reaching a treatment recommendation.",
keywords = "metastatic cancer; communications skills program; shared decison making",
author = "Tattersall, {Martin H. N.} and Kissane, {David W.}",
year = "2017",
language = "English",
isbn = "9780198736134",
pages = "83--90",
editor = "Kissane, {David W.} and Bultz, {Barry D.} and Butow, {Phyllis N.} and Bylund, {Carma L.} and Simon Noble and Susie Wilkinson",
booktitle = "Oxford Textbook of Communication in Oncology and Pallative Care",
publisher = "Oxford University Press",
address = "United Kingdom",
edition = "2nd",

}

Tattersall, MHN & Kissane, DW 2017, Achieving shared treatment decisions. in DW Kissane, BD Bultz, PN Butow, CL Bylund, S Noble & S Wilkinson (eds), Oxford Textbook of Communication in Oncology and Pallative Care. 2nd edn, Oxford University Press, Oxford UK, pp. 83-90.

Achieving shared treatment decisions. / Tattersall, Martin H. N.; Kissane, David W.

Oxford Textbook of Communication in Oncology and Pallative Care. ed. / David W. Kissane; Barry D. Bultz; Phyllis N. Butow; Carma L. Bylund; Simon Noble; Susie Wilkinson. 2nd. ed. Oxford UK : Oxford University Press, 2017. p. 83-90.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

TY - CHAP

T1 - Achieving shared treatment decisions

AU - Tattersall, Martin H. N.

AU - Kissane, David W.

PY - 2017

Y1 - 2017

N2 - Reaching treatment decisions in oncology often involves trade-offs between quality of life and quality of quantity of life. Decisions are best informed by evidence and patients need to understand that their engagement in decision-making is desirable because frequently there is not one best treatment and their values, preferences, and goals are important in reaching shared treatment decisions.In the screening context, screening may identify abnormality that is not cancer but still merit surgery. Some cancers detected by screening may have already metastasized, and the consequence of 'early detection' is extended survival with incurable disease, rather than normal life expectancy. In the adjuvant setting, not every person recommended treatment experiences disease recurrence even if they choose not to receive chemotherapy. Adjuvant treatment may be the standard of care, but patients need to understand that disease recurrence is possible, and the outcome may be extension of disease-free survival, and not disease elimination. In patients with metastatic cancer, systemic treatments at the best may cause tumour shrinkage and prolongation of survival, but some patients will derive no benefit and experience the side effects of chemotherapy.The Institute of Medicine defined patient-centred care as 'care that is respectful of and responsive to individual patient preferences, needs and values' (Barry and Edgman-Levitan 2012, p.780). Involving patients in discussions about treatment options and reaching of shared treatment decision highlights the importance of doctors and patients working together to produce the best outcome possible. Shared decision-making is applicable to most clinical consultations. It is especially important in circumstances where the evidence does not strongly support a single clearly superior option or where a preference-sensitive decision is involved, that is, the decision is likely to be strongly influenced by patient's preferences and values (Hoffmann et al. 2014). Shared decision-making enables research evidence to be incorporated into discussions with the patient, with their preferences explored and considered in reaching a treatment recommendation.

AB - Reaching treatment decisions in oncology often involves trade-offs between quality of life and quality of quantity of life. Decisions are best informed by evidence and patients need to understand that their engagement in decision-making is desirable because frequently there is not one best treatment and their values, preferences, and goals are important in reaching shared treatment decisions.In the screening context, screening may identify abnormality that is not cancer but still merit surgery. Some cancers detected by screening may have already metastasized, and the consequence of 'early detection' is extended survival with incurable disease, rather than normal life expectancy. In the adjuvant setting, not every person recommended treatment experiences disease recurrence even if they choose not to receive chemotherapy. Adjuvant treatment may be the standard of care, but patients need to understand that disease recurrence is possible, and the outcome may be extension of disease-free survival, and not disease elimination. In patients with metastatic cancer, systemic treatments at the best may cause tumour shrinkage and prolongation of survival, but some patients will derive no benefit and experience the side effects of chemotherapy.The Institute of Medicine defined patient-centred care as 'care that is respectful of and responsive to individual patient preferences, needs and values' (Barry and Edgman-Levitan 2012, p.780). Involving patients in discussions about treatment options and reaching of shared treatment decision highlights the importance of doctors and patients working together to produce the best outcome possible. Shared decision-making is applicable to most clinical consultations. It is especially important in circumstances where the evidence does not strongly support a single clearly superior option or where a preference-sensitive decision is involved, that is, the decision is likely to be strongly influenced by patient's preferences and values (Hoffmann et al. 2014). Shared decision-making enables research evidence to be incorporated into discussions with the patient, with their preferences explored and considered in reaching a treatment recommendation.

KW - metastatic cancer; communications skills program; shared decison making

M3 - Chapter (Book)

SN - 9780198736134

SP - 83

EP - 90

BT - Oxford Textbook of Communication in Oncology and Pallative Care

A2 - Kissane, David W.

A2 - Bultz, Barry D.

A2 - Butow, Phyllis N.

A2 - Bylund, Carma L.

A2 - Noble, Simon

A2 - Wilkinson, Susie

PB - Oxford University Press

CY - Oxford UK

ER -

Tattersall MHN, Kissane DW. Achieving shared treatment decisions. In Kissane DW, Bultz BD, Butow PN, Bylund CL, Noble S, Wilkinson S, editors, Oxford Textbook of Communication in Oncology and Pallative Care. 2nd ed. Oxford UK: Oxford University Press. 2017. p. 83-90